Side effect profile of Jadelle implant in Nigerian women during the first 12 months of usage

Emmanuel C. Inyang-Etoh, Anietimfon S. Akpan


Background: Most of the reasons for discontinuation of Jadelle implants by clients are related to the progestogenic side effects, which are dependent on the plasma levels of the hormone. The plasma level of levonorgestrel from Jadelle implant is about 100µg in the first month of insertion, but declines sharply in the first 12months of usage to stabilize at 30µg per day from 24 months of usage. This study was designed to assess the side effect profile of Jadelle implant in users during the first 12months of usage in a view to assessing its acceptability to the clients.

Methods: Data sheet was designed to obtain demographic and clinical parameters of clients and prevailing side effects were surveyed longitudinally over the first 12months of usage.

Results: There was no request for discontinuation of the method and no accidental pregnancy occurred during the period of the study. There was significant disruption of the menstrual pattern of clients over time with 31.1% developing irregular uterine bleeding from 6months of usage, whereas 16.6% of clients became amenorrheic from the 12month of usage. (p= 0.000) Changes in blood pressure and body weight of clients were not significant during the 12month period of the survey. Non menstrual side effects of Jadelle implants, which included headache, breast tenderness, dizziness among clients were noted at 6months of usage but became less prevalent by the 12month of usage.

Conclusions: Jadelle implant proved to be highly effective, safe and acceptable to Nigerian clients during the study period, even though the implant had significant impact on their menstrual pattern.


Jadelle implant, Side effects, Menstrual pattern, Clients, Nigeria

Full Text:



Croxatto HB. Progestin implants for female contraception. Contraception. 2002;65(1):21-7.

Population Council. Norplant levonorgestrel implants. A summary of scientific data. New York: Population Council 1990.

Abasiattai AM, Utuk NM and Inyang-Etoh EC. Sub-dermal contraceptive implants: Profile of acceptors in a tertiary hospital in southern Nigeria. International Journal of Gynecology, Obstetrics and Neonatal care. 2014;1:9-13.

Laphikanont W, Taneepanichskul S. Effects of Jadelle used in Thai women aged between 20-24years in King Chulalongkorn Memorial Hospital. J Med Assoc Thai. 2006;89(6):761-6.

Ramchandran D. Upadhyay UD. Implants: The next generation population reports series, No. 7 Baltimore, INFO Project John Hopkins Bloomberg School of Public Health, October 2007.

Meirik O. Implantable contraceptives for women. Hum Reprod Update Contraception. 2003;9(1):49-59.

Coutinho E, de Sonza J, Athayde C, Barbosa K, Alvarez F, Brache V, et al. Multicentre clinical trial on the efficacy and acceptability of a a single contraception implant of nomegestrel acetate. Uniplant. Contraception. 1996;53:121-5.

Affandi B. An integrated analysis of vaginal bleeding patterns in clinical trials of Implanon. Contraception. 1998;58(6 Suppl):99S-107S.

Basnayake S, Thapa S, Balogh SA. Evaluation of safety, efficacy and acceptability of norplant implants in Sri Lanka. Stud Fam Plann. 1988;19(1):39-47.

Salah M, Ahmed AG, Abo-Eloyoun M, Shaaban MM. Five year experience with Norplant implants in Assiut, Egypt. Contraception. 1987;35(6):543-50.

Ortayli N. Users perspectives on implantable contraceptives for women. Contraception. 2002;65(1):107-11.

Sivin I, Robertson DN, Stern J. Croxatto HB, Diaz S, Coutinho E, et al. Norplant: Reversible implant contraception. Stud Fam Plann. 1980;11:227-35.

Darney PD. Subdermal progestin implant contraception. Curr Opin Obstet Gynecol. 1997;3:470-6.

Darney PD, Atkinson E, Tanner S, Macpherson S, Hellerstein S, Alvarado A, et al. Acceptance and perceptions of Norplant among users in San Francisco, USA. Stud Fam Plann. 1990;21:152-60.

Fraser IS, Tiitinen A, Affandi B, Brache V, Croxatto HB, Diaz S, et al. Norplant consensus statement and background review. Contraception. 1998;57(1):1-9.

Diaz J, Fandes A, Olmos P, Diaz M. Bleeding complaints during the first year of Norplant implants use and their impact on removal rate. Contraception. 1996;53(2):91-5.

Meirik O, Farley TM, Sivin I. Safety and efficacy of levonorgestrel implant, intrauterine device and sterilization. Obstet Gynecol. 2001;97(4):539-47.

Trussell J, Leveque JA, Koenig JD, London R, Borden S, Henneberry J, et al. The economic value of contraception. A comparison of 15 methods. Am J. Public health. 1995;85(4):494-503.

Darney PD, Callegari LS, Swift A, Atkinson ES, Robert AM. Condom practices of urban teens using norplant contraceptives implants, oral contraceptives and condoms for contraception. Am J Obstet Gynecol. 1999;180(4):929-37.

National Population Commission (NPC) Nigeria. National Demographic and Health Survey (NDHS) National Population Commission, Abuja. 2014.

National Population Commission (NPC) Nigeria. Population of Akwa Ibom State. Final Report of the Nigerian Census 2006.

Akwa Ibom State Ministry of Health (AKSMOH). Number of health facilities and health personnel in the state. Updated Statistics of the Akwa Ibom State Ministry of Health for the year 2014.

Enyindah CE, Kasso T. Jadelle subdermal Implants. Preliminary experience in a teaching hospital in the Niger Delta region of Nigeria. Niger J Med. 2011;20(2):270-4.

Thamkhantho M, Jivasak-Apimas S, Angsuwathana S, Chiravacharadej G, Intawong J. One year assessment of women receiving subdermal contraceptive implant at Siriraj Family planning Clinic. J Med Assoc Thai. 2008;91(6):775-80.

Ladipo OA, Akinso SA. Contraceptive implants. Afr J Reprod Health. 2005;9(1):16-23.

Sivin I. Risk and benefits, advantages and disadvantages of levonorgestrel- releasing contraceptive implants. Drug Saf. 2003;26(5):303-35.

Buasang K, Taneepanichskul S. Efficacy of celecoxib on controlling irregular uterine bleeding secondary to jadelle use. J Med Assoc Thai. 2009;92(3):301-7.

Sivin I, Campodonico I, Kiriwat O, Holma P, Diaz S, Wan L. et al. The performance of levonorgestrel and norplant contraceptive implants: a 5 year randomized study. Human Reprod. 1998;13(12):3371-8.